Antibiotics resistance represents one of the biggest problems of global health. Many infections, such as tuberculosis, pneumonia and gonorrhoea are harder to treat because the antibiotics used for their treatment become less effective.

In order to reduce the antibiotic resistance, European Medicines Agency (EMA), Food and Drug Administration (FDA) and Japanese Pharmaceutical and Medical Devices Agency (PMDA) encourage the clinical development of new antimicrobial agents. During the meeting in Vienna, the representatives from the three regulatory agencies have discussed about the design of new clinical trials for testing new treatments for several bacterial infections.

For more information please access European Medicines Agency website.